Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma
- 14 January 2014
- journal article
- research article
- Published by Springer Nature in Tumor Biology
- Vol. 35 (5) , 4651-4657
Abstract
Preoperative evaluation of the risk for metastases in endometrial carcinoma is challenging. The growth of new vessels, angiogenesis, is important for tumor growth and purported to be involved in the metastatic process. The aim of this study was to evaluate the significance of preoperative serum levels and immunohistochemical expression of angiogenic markers in predicting a metastasized disease. Preoperative sera from 98 consecutive women presenting with endometrial carcinoma were collected. Serum concentrations of VEGF, sFLT1, and CD105 were assessed by enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry was used to assess the expression of CD105, VEGF, FLT1, and KDR. The results were correlated to the presence of metastases, presence of deep (≥50 %) myometrial invasion, and the histological grade of the tumor. Tumors with other than endometrioid histology were excluded. Of the 80 evaluable patients, 11 had a metastasized disease. The serum concentration of VEGF was higher in the group with metastases than in the group without metastases (median [range], 743 pg/mL [546–1,183 pg/mL] vs. 383 pg/mL [31–1,524 pg/mL], p < 0.001, respectively). In the multivariable analysis, the concentration of VEGF was the sole independent, albeit weak predictive factor for the presence of metastases (odds ratio, 1.004, 95 % confidence interval, 1.002–1.007; p = 0.001). The immunohistochemical expression of the markers was not associated with any of the clinicopathological features of the tumors. The results of the present study suggest that preoperative serum VEGF concentration correlates with the presence of metastases in endometrioid endometrial carcinoma.Keywords
This publication has 34 references indexed in Scilit:
- Expression of Endoglin in Primary Endometrial CancerOncology, 2011
- A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic useJournal of Cellular and Molecular Medicine, 2010
- Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based ChemotherapyInternational Journal of Gynecological Cancer, 2010
- Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysisBritish Journal of Cancer, 2009
- Endoglin (CD105) as a urinary and serum marker of prostate cancerInternational Journal of Cancer, 2008
- Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancerAmerican Journal of Obstetrics and Gynecology, 2008
- The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histologyInternational Journal of Gynecological Cancer, 2008
- VEGF receptor signalling ? in control of vascular functionNature Reviews Molecular Cell Biology, 2006
- Endoglin (CD105) Expression in Endometrial CarcinomaInternational Journal of Gynecological Pathology, 2003
- Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levelsObstetrics & Gynecology, 2000